Search Results - "Stenger, Elizabeth"

How I treat sickle cell disease with hematopoietic cell transplantation by Stenger, Elizabeth O., Shenoy, Shalini, Krishnamurti, Lakshmanan

“…Sickle cell disease (SCD) leads to significant morbidity and early mortality, and hematopoietic cell transplantation (HCT) is the only widely available cure,…”
Get full text

Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies by Allen, Carl E., Marsh, Rebecca, Dawson, Peter, Bollard, Catherine M., Shenoy, Shalini, Roehrs, Philip, Hanna, Rabi, Burroughs, Lauri, Kean, Leslie, Talano, Julie-An, Schultz, Kirk R., Pai, Sung-Yun, Baker, K. Scott, Andolina, Jeffrey R., Stenger, Elizabeth O., Connelly, James, Ramirez, Alyssa, Bryant, Christopher, Eapen, Mary, Pulsipher, Michael A.

“…Allogeneic hematopoietic cell transplantation (HCT) with myeloablative conditioning for disorders associated with excessive inflammation such as hemophagocytic…”
Get full text

Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity by Stenger, Elizabeth O., Turnquist, Hēth R., Mapara, Markus Y., Thomson, Angus W.

“…Hematopoietic stem cell transplantation is the only curative treatment for many malignant hematologic diseases, with an often critical graft-versus-leukemia…”
Get full text

Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders by Marsh, Rebecca A., Hebert, Kyle, Kim, Soyoung, Dvorak, Christopher C., Aquino, Victor M., Baker, K. Scott, Chellapandian, Deepak, Dávila Saldaña, Blachy, Duncan, Christine N., Eckrich, Michael J., Georges, George E., Olson, Timothy S., Pulsipher, Michael A., Shenoy, Shalini, Stenger, Elizabeth, Lugt, Mark Vander, Yu, Lolie C., Gennery, Andrew R., Eapen, Mary

“…Allogeneic hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis (HLH) disorders is associated with substantial morbidity and mortality…”
Get full text

Sirolimus‐associated pericardial effusion with cardiac tamponade and interstitial pneumonitis in a hematopoietic stem cell transplant recipient by Joo, Su Jin, Yildirim, Inci, Stenger, Elizabeth O., Anderson, Evan J.

“…Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, is a potent immunosuppressant that is increasingly used in prevention and treatment of…”
Get full text

Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease by Stenger, Elizabeth, Giver, Cynthia R., Langston, Amelia, Kota, Daniel, Das, Pankoj Kumar, Chinnadurai, Raghavan, Galipeau, Jacques, Waller, Edmund K., Qayed, Muna

“…Despite the curative potential of hematopoietic cell transplantation (HCT) for hematologic malignancies, graft-versus-host disease (GVHD) remains a substantial…”
Get full text

Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure by Stenger, Elizabeth O., Watkins, Benjamin, Rogowski, Kelsey, Chiang, Kuang-Yueh, Haight, Ann, Leung, Kathryn, Qayed, Muna, Raghunandan, Sharmila, Suessmuth, Yvonne, Kean, Leslie, Horan, John

“…•Four doses of Aba can be safely added to standard 2-drug GVHD prophylaxis in URD HCT for pediatric bone marrow failure.•No severe acute or chronic GVHD was…”
Get full text

Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation by Stenger, Elizabeth O, Krishnamurti, Lakshmanan, Galipeau, Jacques

“…Mesenchymal stromal cells (MSCs) are multipotent progenitor cells known to modulate the immune system and to promote hematopoiesis. These dual effects make…”
Get full text

Reduced-intensity single-unit unrelated cord blood transplant with optional immune boost for nonmalignant disorders by Vander Lugt, Mark T., Chen, Xiaohua, Escolar, Maria L., Carella, Beth A., Barnum, Jessie L., Windreich, Randy M., Hill, Memphis J., Poe, Michelle, Marsh, Rebecca A., Stanczak, Heather, Stenger, Elizabeth O., Szabolcs, Paul

“…Children with many inherited nonmalignant disorders can be cured or their condition alleviated by hematopoietic stem cell transplantation (HSCT). Umbilical…”
Get full text

Immune tolerance strategies in siblings with infantile Pompe disease — Advantages for a preemptive approach to high-sustained antibody titers by Stenger, Elizabeth O., Kazi, Zoheb, Lisi, Emily, Gambello, Michael J., Kishnani, Priya

“…Enzyme replacement therapy (ERT) has led to a significant improvement in the clinical course of patients with infantile Pompe disease (IPD), an autosomal…”
Get full text

HSC engraftment in SCD: a MiSCing piece of the puzzle? by Stenger, Elizabeth

Get full text

Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT by Geerlinks, Ashley V., Scull, Brooks, Krupski, Christa, Fleischmann, Ryan, Pulsipher, Michael A., Eapen, Mary, Connelly, James A., Bollard, Catherine M., Pai, Sung-Yun, Duncan, Christine N., Kean, Leslie S., Baker, K. Scott, Burroughs, Lauri M., Andolina, Jeffrey R., Shenoy, Shalini, Roehrs, Philip, Hanna, Rabi, Talano, Julie-An, Schultz, Kirk R., Stenger, Elizabeth O., Lin, Howard, Zoref-Lorenz, Adi, McClain, Kenneth L., Jordan, Michael B., Man, Tsz-Kwong, Allen, Carl E., Marsh, Rebecca A.

“…•Higher day 0 alemtuzumab levels predict MC and secondary GF after RIC HCT with T-cell–replete grafts.•Day 0 alemtuzumab and post-HCT CXCL9 levels correlated…”
Get full text

Sickle Cell Transplantation Evaluation of Long-term and Late Effects Registry (STELLAR) to Compare Long-term Outcomes After Hematopoietic Cell Transplantation to Those in Siblings Without Sickle Cell Disease and in Nontransplanted Individuals With Sickle Cell Disease: Design and Feasibility Study by Krishnamurti, Lakshmanan, Arnold, Staci D, Haight, Ann, Abraham, Allistair, Guilcher, Gregory Mt, John, Tami, Bakshi, Nitya, Shenoy, Shalini, Syrjala, Karen, Martin, Paul L, Chaudhury, Sonali, Eames, Gretchen, Olowoselu, Olusola Festus, Hsieh, Matthew, De La Fuente, Josu, Kasow, Kimberly A, Stenger, Elizabeth, Mertens, Anne, El-Rassi, Fuad, Lane, Peter, Shaw, Bronwen E, Meacham, Lillian, Archer, David

“…There are sparse data on the long-term and late effects of hematopoietic cell transplantation (HCT) for sickle cell disease (SCD). This study aims to establish…”
Get full text

Hematopoietic Stem Cell Transplantation to Treat Leukodystrophies: Clinical Practice Guidelines from the Hunter's Hope Leukodystrophy Care Network by Page, Kristin M., Stenger, Elizabeth O., Connelly, James A., Shyr, David, West, Tara, Wood, Susan, Case, Laura, Kester, Maureen, Shim, Soo, Hammond, Lauren, Hammond, Matthew, Webb, Christin, Biffi, Alessandra, Bambach, Barbara, Fatemi, Ali, Kurtzberg, Joanne

“…•HSCT is currently the preferred treatment for patients with certain early leukodystrophies.•Indications, donor selection, conditioning, and the unique…”
Get full text

Bone Marrow–Derived Mesenchymal Stromal Cells from Patients with Sickle Cell Disease Display Intact Functionality by Stenger, Elizabeth O, Chinnadurai, Raghavan, Yuan, Shala, Garcia, Marco, Arafat, Dalia, Gibson, Greg, Krishnamurti, Lakshmanan, Galipeau, Jacques

“…Highlights • SCD MSCs exhibit intact phenotype, replication, and immunosuppressive functionality. • IDO is the dominant immunomodulatory pathway used by SCD…”
Get full text

Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases by Stenger, Elizabeth O, Chiang, Kuang-Yueh, Haight, Ann, Qayed, Muna, Kean, Leslie, Horan, John

“…Abstract Transfusion-related alloimmunization is a potent barrier to the engraftment of allogeneic hematopoietic stem cells in patients with nonmalignant…”
Get full text

Red Cell Rheology and Blood Viscosity in Pediatric Individuals Having Received Allogenic Hematopoietic Stem Cell Transplantation or Ex Vivo Autologous Gene Therapy for Sickle Cell Disease by Patel, Ashwin P., Kanne, Celeste K., Stenger, Elizabeth O, John, Tami D., Sheehan, Vivien A.

“…Background: Allogenic hematopoietic stem cell transplantation (HCT) and ex vivo autologous gene therapies (GT) are potentially curative treatments for sickle…”
Get full text

Feasibility of Using the American Time Use Survey to Study the Impact of Sickle Cell Disease and Hematopoietic Cell Transplant on the Daily Lives of Patients and Their Caregivers: A Stellar Study by Khemani, Kirshma, Arnold, Staci D., Bakshi, Nitya, Ross, Diana, Smith, Crystal, Basu, Anirban, Stenger, Elizabeth, Krishnamurti, Lakshmanan

Get full text

IL-12hi Rapamycin-Conditioned Dendritic Cells Mediate IFN-γ–Dependent Apoptosis of Alloreactive CD4+ T Cells In Vitro and Reduce Lethal Graft-Versus-Host Disease by Stenger, Elizabeth O, Rosborough, Brian R, Mathews, Lisa R, Ma, Huihui, Mapara, Markus Y, Thomson, Angus W, Turnquist, Hēth R

“…Abstract Rapamycin (RAPA) inhibits the mechanistic target of rapamycin (mTOR), a crucial immune system regulator. Dendritic cells (DC) generated in RAPA…”
Get full text

Age, GVHD prophylaxis, and timing matter in thrombotic microangiopathy after haematopoietic cell transplantation—A secondary CIBMTR analysis by Schoettler, Michelle L., Westbrook, Adrianna, Watkins, Benjamin, Stenger, Elizabeth, Qayed, Muna, Chonat, Satheesh, Williams, Kirsten M.

“…Summary Most reports of risk factors (RF) for developing transplant‐associated thrombotic microangiopathy (TA‐TMA) and death are derived from paediatric and…”
Get full text